Pharmaceutical Contract Research Services Market by Scale of Operation, Target Therapeutic Areas and Key Geographies : Industry Trends and Global Forecasts, 2021-2030

Pharmaceutical Contract Research Services Market by Scale of Operation, Target Therapeutic Areas and Key Geographies : Industry Trends and Global Forecasts, 2021-2030

  • June 2021 •
  • 503 pages •
  • Report ID: 6154593 •
  • Format: PDF
INTRODUCTION
Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In 2020, the US FDA’s Center for Drug Evaluation and Research approved 35 small molecule drugs, representing 66% of the total number of new molecular entities (NMEs) clearing regulatory review in the same year. It is worth highlighting that the process of drug development, beginning from the discovery of a pharmacological lead to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion. , Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase, actually make it into the clinical phase, and an even lesser number of product candidates enter the market. Therefore, to optimize on internal resource utilization and save costs, innovator companies in the pharmaceutical industry are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs).

Modern CROs offer a plethora of pharmaceutical discovery (such as target discovery & validation, hit identification (using strategies such as high-throughput screening, fragment-based screening, virtual screening, knowledge-based screening and DNA-encoded libraries), and lead generation / optimization) and product development related services, leveraging a variety of advanced technologies to cater to the evolving needs of sponsors / clients. As indicated earlier, engaging third party service providers offers both time and cost related benefits to drug / therapy developers. Currently, over 500 companies / organization claim to be actively providing contract research services for small molecule drugs. In the recent past, many of the service providers in this domain forged strategic alliances and / or acquired other players, in order to further enhance their respective service portfolios and thereby, consolidate their presence in the industry. The aforementioned developments may be attributed to the growing preference for one-stop-shops among sponsor companies, and the gradual acceptance of outsourcing as a viable and beneficial operating model. Based on prevalent trends and projections of how the pharmaceutical pipeline is likely to evolve over the coming years, we believe that demand for pharmaceutical CROs is going to grow at a steady pace. Consequently, the small molecule drug discovery and development services market is anticipated to witness consistent growth till 2030.

SCOPE OF THE REPORT
The "Pharmaceutical Contract Research Services Market, 2021-2030" report features an extensive study on contract service providers engaged in discovery, preclinical and clinical research of small molecule drugs. The study features in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report includes:
• A detailed review of the overall landscape of the pharmaceutical services market, highlighting the contributions of CROs, along with information on their year of establishment, company size, scale of operation (discovery, preclinical and clinical), location of headquarters, type(s) of services offered (target discovery & validation, hit identification, hit-to-lead & lead generation, lead optimization, bioanalytical studies, other preclinical services, clinical trials related services, consulting and regulatory affairs management), hit identification strategy used (high-throughput screening, fragment based screening, virtual screening (structure based virtual screening, ligand based virtual screening and unspecified virtual screening), knowledge based screening, DNA Encoded Library (DEL) based screening and others), type of business model (fee-for-service and full time equivalent) and target therapeutic area.
• Elaborate profiles of prominent CROs engaged in offering pharmaceutical related services. Each company profile features a brief overview of the company, its financial information (if available), service portfolio and recent developments and an informed future outlook.
• An insightful competitiveness analysis, highlighting prominent pharmaceutical contract service providers based on supplier strength (considering a company’s years of experience), and service strength (which takes into account the service offerings, scale of operation, hit identification strategies and subject specific agreements).
• An analysis of the recent collaborations (signed since 2018) focused on the CROs offering pharmaceutical related services, based on various parameters, such as year of agreement, type of agreement, scale of operation and target therapeutic area.
• A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2018-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition and geographical location of the companies.
• A region-wise, detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider. It features an informed estimate of direct and indirect expenses taking into consideration close to 100 relevant parameters over a span of 20 years.
• A case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical CROs market over the coming decade. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] scale of operation (discovery services, preclinical services and clinical stage services), [B] target therapeutic area (cardiovascular disorder, dermatological disorders, infectious disorder, inflammatory disorder, neurological disorder, oncological disorder, ophthalmological disorder, respiratory disorder and other disorders) and [C] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
• Annual reports
• Investor presentations
• SEC filings
• Industry databases
• News releases from company websites
• Government policy documents
• Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the pharmaceutical CROs market in the mid to long term.

Chapter 3 provides a general introduction to the process of drug discovery and development. The chapter highlights the challenges associated with small molecule drug discovery along with a detailed discussion on the need for outsourcing within the pharmaceutical industry and guidelines for selecting the right service provider.

Chapter 4 provides a comprehensive overview of the global pharmaceutical services market, highlighting the contributions of over 500 CROs. It features a detailed assessment of the market, based on a number of relevant parameters, such as year of establishment, company size, scale of operation (discovery, preclinical and clinical), location of headquarters, types of services offered (target discovery & validation, hit identification, hit-to-lead and lead generation, lead optimization, bioanalytical studies, other preclinical services, clinical trials related services, consulting and regulatory affairs management), hit identification strategy used (high-throughput screening, fragment based screening, virtual screening (structure based virtual screening, ligand based virtual screening and unspecified virtual screening), knowledge based screening, DNA Encoded Library (DEL) based screening and others), type of business model (fee-for-service and full time equivalent) and target therapeutic area.

Chapter 5 provides detailed profiles of some of the key players that are active in the pharmaceutical contract research services market. Each profile presents a brief overview of the company, its financial information (if available), service portfolio and recent developments and an informed future outlook.

Chapter 6 features a comprehensive company competitiveness analysis, highlighting prominent pharmaceutical contract service providers based in North America, Europe, Asia-Pacific and Rest of the world, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (considering a company’s years of experience), and service strength (which takes into account the service offerings, scale of operation, hit identification strategies and subject specific agreements).

Chapter 7 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2018. It includes brief descriptions of the various partnership models (including acquisition, clinical trial, platform utilization, product development, research, research and development, service, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation and target therapeutic area. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 presents a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2018-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition and geographical location of the companies.

Chapter 9 presents an insightful market forecast analysis, highlighting the likely growth of the pharmaceutical CROs market till the year 2031. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] scale of operation (discovery services, preclinical services and clinical stage services), [B] target therapeutic area (cardiovascular disorder, dermatological disorder, infectious disorder, inflammatory disorder, neurological disorder, oncological disorder, ophthalmological disorder, respiratory disorder and other disorders) and [C] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).

Chapter 10 features a detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider in key geographical regions (US, Europe and Asia-Pacific). It presents estimated direct and indirect expenses taking into consideration close to 100 relevant parameters over a span of 20 years.

Chapter 11 features a case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered.

Chapter 12 features the transcript of the discussion(s) held with key stakeholder(s) in the industry.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.